Scott Requadt

Track

Insider profile

Currently holds positions in Tourmaline Bio Inc, ESSA Pharma Inc and VBI Vaccines (Delaware) Inc

Performance

Overall performance
1.0
Performance over holding periods
1.0
30 days 90 days 120 days
Average return -14% 8.2% 15.1%
Success rate 15% 68% 82%
Transactions
4 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Chief Executive Officer, Director Tourmaline Bio Inc None -
Director ESSA Pharma Inc Jan. 6, 2016 -
Independent Director VBI Vaccines (Delaware) Inc Dec. 8, 2015 -
Independent Director Tectonic Therapeutic Inc July 1, 2016 - Jan. 7, 2019
Scott Requadt's trades of Tourmaline Bio Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Proposed sale
Price
329.42
Quantity 33,599
Value US$399,758
Transaction date
Purchase
Price
333.96
Quantity 28,965 +33.7%
Value US$355,012
Transaction date
Purchase
Price
67.47
Quantity 91,573 -35.4%
Value US$513,273
Transaction date
Purchase
Price
4.24
Quantity 5,528 +1.2%
Value US$23,439
Transaction date
Purchase
Price
3.75
Quantity 9,444 +2.1%
Value US$35,412
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2023-07-05 2023-07-05
PrS Proposed sale
33,599
329.42
US$399,758 		33,599 329.42 US$399,758
2022-08-02 2022-07-29
B Purchase
28,965 +33.7%
333.96
US$355,012 		28,965 +33.7% 333.96 US$355,012
2022-07-28 2022-07-28
B Purchase
91,573 -35.4%
67.47
US$513,273 		91,573 -35.4% 67.47 US$513,273
2022-07-28 2022-07-26
B Purchase
5,528 +1.2%
4.24
US$23,439 		5,528 +1.2% 4.24 US$23,439
2022-07-26 2022-07-22
B Purchase
9,444 +2.1%
3.75
US$35,412 		9,444 +2.1% 3.75 US$35,412